2026.04.01 衛教骨骼

骨密度報告紅字好嚇人？看懂 2 款進階骨鬆新藥，找回硬朗好骨力

Name: 骨密度報告紅字好嚇人？看懂 2 款進階骨鬆新藥，找回硬朗好骨力 - 博田國際健康管理中心
Creator: 黃柏誠醫師
Published: 2026-04-01T15:45:43+08:00

選對武器應戰：Denosumab 適合長期穩定防守，每半年一針鎖住骨質；Romosozumab 適合極高風險者快速造骨，每月一針限用一年。
接力治療不斷線：無論使用哪種藥物，都不能中途自行停藥。特別是 Romosozumab 用滿一年後，必須轉換其他藥物接力防守。
原料與刺激並重：藥物只是輔助，每天仍需攝取充足的鈣質與維生素Ｄ，並搭配適度的承重運動，才能真正養出好骨力。

骨質疏鬆的進階治療選項中，Denosumab 與 Romosozumab 都能有效增加骨密度並降低骨折風險。前者適合需要長期穩定控制的高風險族群，後者適合極高骨折風險的患者進行一年期的快速造骨。用藥後千萬不能隨便停藥，一定要配合醫師規劃後續的保養方案，同時補足鈣質與維生素Ｄ，才能真正保骨本。

陳媽媽今年六十五歲，平時看起來精神很好，每天都會去公園散步。上個月她在公園牽著剛滿兩歲的孫子，遇到不平的地磚稍微絆了一下。她下意識用手掌撐了一下地板，沒想到手腕竟然就這樣骨折了。

陪同來看診的女兒滿臉擔憂，拿著剛剛出爐的骨密度檢測報告。報告上的數值顯示 T 值來到負三點零，旁邊還標記著醒目的紅字。女兒著急地問：「媽媽每天都有喝牛奶，出門也會曬太陽，怎麼骨頭會變得這麼脆？」

拿到報告的當下，很多人第一個念頭是：完了，我是不是要生病了？其實骨密度檢測就像是幫身體的骨架做一次全面的壓力測試。及早發現地基不穩，我們就有機會趕緊補強，避免未來發生更嚴重的髖部或脊椎骨折。

傳統的口服保骨藥物對於輕度或中度的患者很有幫助。當骨質流失的情況比較嚴重，甚至已經發生過骨折時，我們就需要更強大的武器來幫忙。這時候，醫學界有兩款很有效的進階針劑藥物，分別是 Denosumab 和 Romosozumab。

今天我們就來好好聊聊這兩種藥物的作用方式。了解它們怎麼在身體裡工作，你和家人在面對治療選擇時，心裡會踏實很多。

為什麼需要提醒？

我們的骨骼其實不是一成不變的死物，它每天都在進行新陳代謝。身體裡面有兩群細胞日夜不停地工作，維持著骨頭的健康與強韌。你可以把它們想像成一個都市更新的工程團隊。

其中一群叫做破骨細胞，負責把老舊、微小受損的骨質吸收掉。另一群叫做造骨細胞，負責在空出來的地方填上新的骨質。年輕的時候，這兩群細胞的合作非常默契，拆多少就建多少，骨頭始終維持在最佳狀態。

隨著年紀增長，特別是女性在更年期之後，荷爾蒙的變化會打破這個平衡。負責拆除的細胞變得非常活躍，而負責建設的細胞卻開始怠工。久而久之，骨頭的結構就會變得空洞脆弱，這就是骨質疏鬆的由來。

叫停拆除大隊的 Denosumab

如果你身體裡的拆除大隊實在太過失控，我們就需要派糾察隊去管制他們。Denosumab 的運作原理，就像是給這群破骨細胞下達了強制的停工令。

每半年打一針，它能精準地抑制破骨細胞的活性，讓老舊骨質的流失速度大幅減緩。建設團隊就可以慢慢把進度趕上來，逐漸把骨頭的空洞補齊。

這是一種非常穩定且持久的防守策略。只要按時施打，骨頭的密度就能夠穩步回升，把地基重新穩固下來。

雙管齊下的超級工程團隊 Romosozumab

遇到有些患者的骨質已經嚴重掏空，光是叫停拆除大隊已經來不及了。這時候我們需要 Romosozumab 來執行更積極的救援計畫。它不僅能讓破骨細胞暫停工作，還能同時給造骨細胞打一劑強心針。

這就像是政府直接撥了一筆特別預算，擴編了建設團隊的規模，要求他們日夜趕工蓋新大樓。在這種雙管齊下的策略下，骨頭生成的速度會變得非常快。

這種藥物特別適合那些骨折風險極高，急需在短時間內拉抬骨密度的長輩。不過這種超級工程有時間限制，通常只會連續進行十二個月。

研究怎麼說？

了解完這些藥物的基本原理，你可能會問：這兩種藥物真的有那麼神奇嗎？我們來看看大型醫學研究提供的客觀數據。醫學界對於這兩種藥物的效果，已經有非常充分且嚴謹的驗證。

這些數字聽起來可能有點距離感，我會把它們翻譯成大家都能理解的日常情況。這個差異不是巧合，是真的有效。

長期穩定防守的 Denosumab

一項名為 FREEDOM 的大型臨床研究，專門觀察 Denosumab 在停經後婦女身上的表現。研究結果顯示，使用三年的患者，脊椎骨折的風險大幅下降了百分之六十八[6]。髖部骨折的風險也減少了百分之四十[6]。

這代表什麼意思呢？如果有一百個原本可能會因為彎腰搬花盆而閃到腰、甚至脊椎壓迫性骨折的長輩。經過治療後，有將近七十個人可以完全避免這場意外[6]。更棒的是，這種保護力非常持久，後續的延伸研究證實，連續使用十年的患者，骨密度依然在持續成長[1][5]。

只要規律每半年接受一次皮下注射，身體就像穿上了一件隱形的防彈衣[2]。它能讓骨頭的厚實度慢慢累積，對於需要長期抗戰的長輩來說，是一個非常可靠的選擇[1]。

快速強化重建的 Romosozumab

Romosozumab 雖然是相對較新的藥物，但它的造骨爆發力讓很多專家印象深刻。在 FRAME 這個研究計畫中，患者接受每個月一次的注射，連續治療十二個月。結果發現，脊椎骨折的發生率在第一年就劇降了百分之七十三[10]。

如果把它直接拿來和 Denosumab 做一對一的比賽，Romosozumab 增加骨密度的速度明顯贏過對方。在治療滿一年的時候，使用 Romosozumab 的患者腰椎骨密度增加了百分之十二點五[8]。而使用 Denosumab 的患者只增加了百分之七點二[8]。

在另一項針對已經嚴重骨折患者的 ARCH 研究裡，Romosozumab 的表現甚至超越了傳統的口服藥物 Alendronate[11]。它能更全面地保護脊椎、髖部以及其他非脊椎部位的骨骼[11]。對於從來沒有接受過其他骨鬆治療的初診患者，這種新藥能帶來最大的進步幅度[15]。

接力治療效果更好

既然 Romosozumab 這麼厲害，為什麼只能打一年呢？因為身體的造骨機制有其極限，經過十二個月的密集趕工後，造骨細胞的活躍度就會自然下降。如果這時候直接停藥，好不容易蓋好的骨質很快就會流失掉。

所以醫學界發展出了一套非常聰明的「接力治療」策略。在打完一年的 Romosozumab 之後，立刻接手使用 Denosumab 或是傳統的雙磷酸鹽類藥物[1][12]。

研究數據明確顯示，這種「先強攻、後穩守」的組合拳，效果超級好。經過兩年的接力治療，患者的腰椎骨密度可以比單純只用 Denosumab 的人多出百分之九點三[13]。這能將極度脆弱的骨頭，快速拉抬到安全的標準線上[14]。

我需要進一步處理嗎？

看到這裡，你心裡可能已經在盤算，自己或家人到底適合哪一種方案。每個人的身體狀況都不同，我整理了一個簡單的對照表。你可以對照健檢報告上的數值，初步了解自己可能落在哪個區間。

指標狀況	建議行動	適合誰	追蹤時間
T值介於 -1.0 到 -2.5 之間 (骨質缺乏)	調整生活作息，加強營養與運動。	尚未有骨折紀錄，數值輕微紅字的民眾。	每一到兩年定期做一次雙能量X光骨密度檢測 (DXA)。
T值小於 -2.5 (骨質疏鬆)	尋求醫師評估，考慮開始使用口服藥物或 Denosumab 長期保養。	骨鬆風險較高，腎功能正常且能配合長期規律回診的患者。	開始治療後，每年追蹤一次骨密度與抽血檢查骨轉換指標。
T值小於 -3.0，或已經發生過脆弱性骨折	建議與醫師討論是否適合先使用 Romosozumab 快速拉高骨密度。	極高骨折風險，且過去一年內沒有心肌梗塞或中風病史的患者。	Romosozumab 治療滿一年後，必須立刻回診轉換接力藥物。

有沒有副作用或風險？

醫學上沒有任何一種藥物是完美的，了解風險才能更安心地接受治療。首先來談談 Denosumab，它最常被忽略的風險就是「絕對不能隨便停藥」。一旦延誤打針的時間，被壓抑已久的破骨細胞會出現報復性的反彈。

這種反彈會導致骨質在幾個月內大量流失，甚至引發多發性的脊椎骨折[1]。如果你因為拔牙或其他原因必須暫停 Denosumab，一定要請醫師開立像是 Alendronate 或 Zoledronate 這些藥物來接手保護[1]。此外，對於晚期慢性腎臟病患者，Denosumab 容易引起嚴重的低血鈣，需要特別小心[2][5]。

至於 Romosozumab，它最大的限制在於心血管方面的安全疑慮。在部分研究中發現，它可能會微幅增加心血管事件的發生率[12]。因此，如果患者在過去一年內曾經發生過心肌梗塞或中風，醫師絕對會避開這個選項[3]。

另外，這兩種藥物都有極罕見的顎骨壞死與非典型股骨骨折的風險[1][12]。這些名詞聽起來嚇人，但發生的機率其實非常非常低。只要保持良好的口腔衛生，在進行拔牙或植牙前事先告知牙醫師你的用藥紀錄，就能把風險降到最低。

醫師建議怎麼做？

看懂了藥物的特性與風險，接下來的日常保養才是真正決定治療成敗的關鍵。藥物只是幫我們打通了任督二脈，建構骨頭需要的磚塊和水泥，還是得靠我們自己吃進去。這裡有幾個非常實用的生活建議，請把它們落實到每一天的生活中。

確實回診，絕不擅自停藥

骨質疏鬆是一種慢性的無聲疾病，不痛不癢，所以很容易讓人忘記回診。不管你選擇哪一種針劑，都要把打針的日期記在日曆最顯眼的地方。特別是 Denosumab，每半年的回診就像是定期繳保費，千萬不能斷掉。

如果真的遇到特殊狀況需要延期，一定要打電話回診所跟醫師討論。我們會幫你想辦法調整用藥節奏，絕對不能自己默默地就不來了。

營養補充要到位

前面提過，這兩種藥物都會把血液裡的鈣質快速搬進骨頭裡。這會導致血液中的鈣濃度下降，所以你必須補充足夠的原料。每天至少要攝取一千毫克的鈣質，來源可以是牛奶、小魚乾、黑芝麻或是傳統豆腐[2]。

除了鈣質，維生素Ｄ也是少不了的幫手，它能幫忙腸道吸收鈣質。除了每天適度曬太陽，也可以考慮額外補充至少四百國際單位的維生素Ｄ保健品[5]。

找出適合的承重運動

骨頭很聰明，你越去刺激它，它就會長得越結實。散步雖然好，但對於增加骨密度的幫助比較有限。你需要加入一些有重量負荷的運動。

像是快走、爬樓梯、跳繩，或者是在專業教練指導下進行輕度的重量訓練。這些都能給骨骼適當的壓力訊號，告訴它們：「我還需要你們，請繼續保持堅固。」

常見誤解澄清

在診間，我常聽到患者對骨鬆治療有一些根深蒂固的誤會。這很容易導致他們放棄治療，或是用了錯誤的方式照顧自己。讓我來幫大家釐清這些常見的迷思。

打完一年 Romosozumab，骨頭變硬就可以不用理它了對嗎？

真相：絕對不行。Romosozumab 只是幫你在短期內把大樓蓋好，如果沒有後續的保全系統介入，這棟大樓很快就會被破壞掉。打滿十二個月之後，一定要立刻轉換成 Denosumab 或其他抗骨吸收藥物，把辛苦賺來的骨本牢牢鎖住。

骨質疏鬆用藥會造成下巴骨頭壞死，能不能只靠吃鈣片就好？

真相：這種罕見副作用的發生率大約只有萬分之一到十萬分之一。相比之下，因為嚴重骨鬆導致髖部骨折，進而臥床甚至危及生命的風險高達百分之二十。兩權相害取其輕，只要做好牙齒保健，規律洗牙，這個風險是完全可以控制的。光靠鈣片無法阻止骨質流失，就像大樓地基壞了，只買幾包水泥放在旁邊是沒用的。

我已經七十幾歲了，現在才開始打針保養骨頭還來得及嗎？

真相：永遠來得及。醫學研究已經證明，即使是八十歲以上的長輩，接受完整的骨質疏鬆治療後，依然能顯著降低再次骨折的機率。把骨頭顧好，能讓自己自由走動、不用依賴輪椅，這是維持晚年生活尊嚴最關鍵的一步。

重點整理

看完這篇長長的文章，希望你對骨質疏鬆的進階治療有了更清晰的概念。最後幫大家總結三個馬上可以帶走的重要觀念：

選對武器應戰：Denosumab 適合長期穩定防守，每半年一針鎖住骨質；Romosozumab 適合極高風險者快速造骨，每月一針限用一年。
接力治療不斷線：無論使用哪種藥物，都不能中途自行停藥。特別是 Romosozumab 用滿一年後，必須轉換其他藥物接力防守。
原料與刺激並重：藥物只是輔助，每天仍需攝取充足的鈣質與維生素Ｄ，並搭配適度的承重運動，才能真正養出好骨力。

English Version

Alarming Bone Density Report? Understanding 2 Advanced Osteoporosis Medications to Rebuild Strong Bones

Among advanced treatment options for osteoporosis, both Denosumab and Romosozumab effectively increase bone density and reduce fracture risk. The former is suited for high-risk patients needing long-term, steady control; the latter is ideal for those at extremely high fracture risk who need a one-year intensive bone-building phase. After either treatment, you must never stop abruptly -- always work with your physician to plan the next phase of therapy, and ensure adequate calcium and vitamin D intake to truly protect your bone reserves.

Mrs. Chen is sixty-five and usually looks the picture of health, taking daily walks in the park. Last month, while holding the hand of her two-year-old grandchild at the park, she stumbled slightly on an uneven paving tile. She instinctively braced herself with her palm, and her wrist fractured just like that.

Her daughter, who accompanied her to the clinic, was visibly worried, holding the just-printed bone density report. The T-score read negative 3.0, flagged in bold red. Her daughter anxiously asked: "Mom drinks milk every day and gets sun when she goes out -- how can her bones be this fragile?"

When patients first see results like these, the immediate thought is usually: "It's over -- am I seriously ill?" In truth, bone density testing is like a comprehensive stress test for your skeleton. Catching an unstable foundation early gives us the opportunity to reinforce it before a more serious hip or spinal fracture occurs.

Traditional oral bone-protecting medications are helpful for mild to moderate cases. When bone loss is more severe or fractures have already occurred, we need more powerful weapons. The medical world has two highly effective injectable options: Denosumab and Romosozumab.

Let us take a closer look at how these two medications work inside the body. Understanding their mechanisms will give you and your family much greater confidence when facing treatment decisions.

Why Does This Matter?

Our bones are not lifeless, unchanging structures -- they undergo daily renewal. Two groups of cells work around the clock to maintain bone health and strength. Think of them as an urban renewal team.

One group, the osteoclasts, is responsible for demolishing old, micro-damaged bone. The other group, the osteoblasts, fills in the cleared spaces with fresh bone. In youth, these two teams collaborate perfectly -- whatever is torn down is rebuilt, keeping bones in optimal condition.

With age, especially after menopause in women, hormonal shifts upset this balance. The demolition crew becomes hyperactive while the construction crew starts slacking off. Over time, bone structure becomes hollow and fragile -- this is osteoporosis.

Denosumab: Stopping the Demolition Crew

When the demolition crew in your body is out of control, we need to dispatch an enforcement squad. Denosumab works by issuing a mandatory stop-work order to the osteoclasts.

With one injection every six months, it precisely suppresses osteoclast activity, dramatically slowing the rate of bone loss. The construction team can then gradually catch up, filling in the hollow spaces. This is a very stable, long-term defensive strategy. As long as injections continue on schedule, bone density steadily recovers.

Romosozumab: A Dual-Action Super Construction Team

For patients whose bones are already severely hollowed out, simply stopping the demolition crew may not be enough. That is where Romosozumab comes in with a more aggressive rescue plan. It not only pauses the osteoclasts but simultaneously supercharges the osteoblasts.

This is like the government disbursing a special budget to expand the construction crew and demanding they work day and night on new buildings. Under this dual-action approach, new bone forms at a remarkable pace.

This medication is especially suited for elderly patients at extremely high fracture risk who need rapid bone density improvement. However, this intensive construction phase has a time limit -- typically twelve months only.

What Does the Research Say?

Long-Term Steady Defense: Denosumab

The landmark FREEDOM trial specifically studied Denosumab in postmenopausal women. After three years of treatment, spinal fracture risk dropped by sixty-eight percent[6], and hip fracture risk decreased by forty percent[6].

What does that mean? If one hundred elderly patients were otherwise at risk of a spinal compression fracture from bending over to pick up a flowerpot, nearly seventy of them could completely avoid that injury after treatment[6]. Better still, this protection is remarkably durable -- extension studies confirmed that patients who continued for ten years saw bone density still increasing[1][5].

With regular injections every six months, the body essentially wears an invisible suit of armor[2]. Bone thickness accumulates gradually, making this a very reliable choice for patients who need long-term protection[1].

Rapid Reinforcement: Romosozumab

Although Romosozumab is relatively newer, its bone-building power has impressed many experts. In the FRAME study, patients received monthly injections for twelve months. Spinal fracture rates plummeted by seventy-three percent in the first year alone[10].

In direct head-to-head comparisons with Denosumab, Romosozumab increased bone density significantly faster. At twelve months, Romosozumab patients gained 12.5% in lumbar spine density[8], compared to 7.2% with Denosumab[8].

In the ARCH study of patients with prior severe fractures, Romosozumab even outperformed the traditional oral medication Alendronate[11], providing more comprehensive protection across the spine, hip, and other non-vertebral sites[11].

Relay Therapy for Even Better Results

If Romosozumab is so powerful, why limit it to one year? Because the body's bone-building capacity has natural limits -- after twelve months of intensive construction, osteoblast activity naturally wanes. Stopping at that point without follow-up treatment would cause the hard-won bone gains to rapidly disappear.

That is why the medical community developed a brilliant "relay therapy" strategy: immediately after completing one year of Romosozumab, patients transition to Denosumab or a bisphosphonate[1][12].

Research data clearly shows this "attack first, then defend" combination is incredibly effective. After two years of relay therapy, lumbar spine bone density is 9.3% higher than with Denosumab alone[13], rapidly elevating extremely fragile bones to a safe standard[14].

Do I Need Further Evaluation?

Finding | Recommended Action | Who It Applies To | Follow-Up Timeline
T-score between -1.0 and -2.5 (osteopenia) | Adjust lifestyle, strengthen nutrition and exercise. | People with mildly flagged values and no fracture history | DXA scan every one to two years
T-score below -2.5 (osteoporosis) | Seek physician evaluation; consider oral medication or long-term Denosumab. | Higher osteoporosis risk, normal kidney function, able to attend regular follow-ups | Annual bone density and bone turnover marker tests after starting treatment
T-score below -3.0, or prior fragility fracture | Discuss whether Romosozumab is appropriate for rapid bone density recovery. | Extremely high fracture risk, no heart attack or stroke in the past year | Must return for relay medication immediately after completing one year of Romosozumab

Are There Side Effects or Risks?

No medication is perfect, and understanding risks allows you to accept treatment with greater peace of mind. For Denosumab, the most frequently overlooked risk is that you must never skip or stop injections on your own. If an injection is delayed, the long-suppressed osteoclasts can rebound aggressively, causing rapid bone loss and even multiple spinal fractures within months[1]. If you must pause Denosumab for dental procedures or other reasons, your doctor must prescribe a bridging medication like Alendronate or Zoledronate[1]. Additionally, Denosumab can cause severe hypocalcemia in patients with advanced chronic kidney disease[2][5].

For Romosozumab, the main limitation concerns cardiovascular safety. Some studies found a slight increase in cardiovascular events[12]. Therefore, if a patient has had a heart attack or stroke in the past year, physicians will avoid this option entirely[3].

Both medications carry extremely rare risks of osteonecrosis of the jaw and atypical femoral fracture[1][12]. While these terms sound alarming, the actual incidence is very, very low. Maintaining good oral hygiene and informing your dentist about your medications before any dental procedures keeps the risk minimal.

What Does the Doctor Recommend?

Never Miss an Appointment, Never Stop on Your Own

Osteoporosis is a chronic, silent disease -- painless and easy to forget about. Regardless of which injectable you choose, mark the injection date prominently on your calendar. Especially with Denosumab, each six-month visit is like paying an insurance premium -- you cannot let it lapse.

If a special circumstance requires postponement, call the clinic to discuss options. We will help adjust your schedule. Just do not quietly disappear.

Keep Your Nutritional Supply Lines Open

Both medications rapidly shuttle calcium from the bloodstream into bone, which can lower blood calcium levels. You must replenish the raw materials: at least one thousand milligrams of calcium daily from sources like milk, small dried fish, black sesame, or traditional tofu[2]. Vitamin D is equally essential to help intestinal calcium absorption. Beyond moderate daily sun exposure, consider supplementing at least four hundred international units of vitamin D[5].

Find the Right Weight-Bearing Exercise

Bones are smart -- the more you stimulate them, the stronger they grow. Walking is good, but its impact on bone density is limited. You need some weight-bearing activity: brisk walking, stair climbing, jump rope, or light resistance training under professional guidance. These activities send pressure signals to your bones telling them: "I still need you -- stay strong."

Common Misconceptions Clarified

After finishing one year of Romosozumab, my bones are stronger now so I can stop treatment, right?

The truth: Absolutely not. Romosozumab only builds the structure in the short term. Without a subsequent security system in place, that structure will quickly deteriorate. After twelve months, you must immediately transition to Denosumab or another anti-resorptive medication to lock in those hard-earned gains.

Osteoporosis drugs can cause jawbone necrosis -- can I just take calcium pills instead?

The truth: This rare side effect occurs in roughly one in ten thousand to one in one hundred thousand cases. By comparison, the risk of a hip fracture leading to bed rest and even death from severe osteoporosis is about twenty percent. Weigh the risks: as long as you maintain good dental hygiene and regular dental cleanings, this risk is entirely manageable. Calcium pills alone cannot stop bone loss -- it is like setting a few bags of cement next to a building with a crumbling foundation and expecting the problem to fix itself.

I am in my seventies -- is it too late to start treatment?

The truth: It is never too late. Research has proven that even patients over eighty who receive full osteoporosis treatment can significantly reduce their risk of further fractures. Keeping your bones strong means staying mobile and independent, without relying on a wheelchair -- and that is the most important factor in maintaining dignity in later years.

Key Takeaways

Choose the right weapon: Denosumab is best for long-term steady defense with one injection every six months; Romosozumab is best for extremely high-risk patients needing rapid bone-building with monthly injections for one year.

Relay therapy must not be interrupted: Regardless of which medication you use, never stop on your own. After completing one year of Romosozumab, you must immediately switch to a follow-up medication.

Raw materials and stimulation go hand in hand: Medication is an aid; you still need adequate daily calcium and vitamin D intake, combined with weight-bearing exercise, to truly build lasting bone strength.

參考文獻

Walker MD, Shane E. Postmenopausal Osteoporosis. The New England Journal of Medicine. 2023;389(21):1979-1991. DOI: 10.1056/NEJMcp2307353
Qaseem A, Hicks LA, Etxeandia-Ikobaltzeta I, et al. Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults: A Living Clinical Guideline From the American College of Physicians. Annals of Internal Medicine. 2023;176(2):224-238. DOI: 10.7326/M22-1034
Chen Y, Zhu J, Zhou Y, Peng J, Wang B. Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women. Frontiers in Pharmacology. 2021;12:588095. DOI: 10.3389/fphar.2021.588095
Ye C, Ebeling P, Kline G. Osteoporosis. Lancet (London, England). 2025;406(10514):2003-2016. DOI: 10.1016/S0140-6736(25)01385-6
Cummings SR, San Martin J, McClung MR, et al. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine. 2009;361(8):756-65. DOI: 10.1056/NEJMoa0809493
Kobayakawa T, Miyazaki A, Saito M, et al. Denosumab Versus Romosozumab for Postmenopausal Osteoporosis Treatment. Scientific Reports. 2021;11(1):11801. DOI: 10.1038/s41598-021-91248-6
Hu M, Zhang Y, Guo J, et al. Meta-Analysis of the Effects of Denosumab and Romosozumab on Bone Mineral Density and Turnover Markers in Patients With Osteoporosis. Frontiers in Endocrinology. 2023;14:1188969. DOI: 10.3389/fendo.2023.1188969
Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. The New England Journal of Medicine. 2016;375(16):1532-1543. DOI: 10.1056/NEJMoa1607948
Saag KG, Petersen J, Brandi ML, et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. The New England Journal of Medicine. 2017;377(15):1417-1427. DOI: 10.1056/NEJMoa1708322
Morin SN, Leslie WD, Schousboe JT. Osteoporosis. JAMA. 2025;334(10):894-907. DOI: 10.1001/jama.2025.6003
Cosman F, Oates M, Betah D, et al. Romosozumab Followed by Denosumab Versus Denosumab Only: A Post Hoc Analysis of FRAME and FRAME Extension. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research. 2024;39(9):1268-1277. DOI: 10.1093/jbmr/zjae116
Lewiecki EM, Dinavahi RV, Lazaretti-Castro M, et al. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study. Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research. 2019;34(3):419-428. DOI: 10.1002/jbmr.3622
Richardson-Thornton I, Brennan SC, Liu L, et al. A New Age of Osteoanabolic Therapy? A Real-World, Two-Centre Study Comparing Effects of Romosozumab, Teriparatide, and Antiresorptive Therapies for Osteoporosis. Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2026;:10.1007/s00198-025-07808-3. DOI: 10.1007/s00198-025-07808-3

黃柏誠醫師

✓ 認證作者衛福部醫事人員

博田國際健康管理中心醫療主任、家庭醫學專科醫師。台灣大學醫學系醫學士、高雄醫學大學藥學碩士、美國哈佛 BIDMC 老年醫學科訪問醫師、體適能健身 C 級指導員認證。專長預防醫學與減重醫學，擅長以資訊工具優化臨床流程。

醫療免責聲明

本文內容僅供衛教參考，不構成個人醫療建議、診斷或治療方案。任何健康問題請諮詢您的主治醫師或合格醫療專業人員。博田國際健康管理中心對依據本文內容所做之決定不承擔任何責任。

最後審閱日期：2026 年 4 月 1 日

搜尋

熱門關鍵字

骨密度報告紅字好嚇人？看懂 2 款進階骨鬆新藥，找回硬朗好骨力

為什麼需要提醒？

叫停拆除大隊的 Denosumab

雙管齊下的超級工程團隊 Romosozumab

研究怎麼說？

長期穩定防守的 Denosumab

快速強化重建的 Romosozumab

接力治療效果更好

我需要進一步處理嗎？

有沒有副作用或風險？

醫師建議怎麼做？

確實回診，絕不擅自停藥

營養補充要到位

找出適合的承重運動

常見誤解澄清

重點整理

參考文獻

黃柏誠醫師

搜尋

熱門關鍵字

骨密度報告紅字好嚇人？看懂 2 款進階骨鬆新藥，找回硬朗好骨力

為什麼需要提醒？

叫停拆除大隊的 Denosumab

雙管齊下的超級工程團隊 Romosozumab

研究怎麼說？

長期穩定防守的 Denosumab

快速強化重建的 Romosozumab

接力治療效果更好

我需要進一步處理嗎？

有沒有副作用或風險？

醫師建議怎麼做？

確實回診，絕不擅自停藥

營養補充要到位

找出適合的承重運動

常見誤解澄清

重點整理

參考文獻

黃柏誠醫師

其他健康專欄